Form 13-F position report

ISHARES BIOTECHNOLOGY ETF

Reported by Signature Wealth Management Partners LLC

ETF profile Manager portfolio Source filing
IBB CUSIP 464287556 Manager CIK 0001824694
Latest reported change

Reported 11,046 shares, down 732 (6.2%) from the prior quarter.

Reported value -6.2%; share count -6.2% vs. the prior quarter.

Reduced
% of reported 13F value 1.15% This manager · Q2 2024
Shares 11,046 Quarter-end amount reported
Reported value $1,516,174 Fair value at quarter end
Consecutive quarters held 15 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q3 2026 Unchanged 7,606 0 (0.0%) 0.68% $1,601,291 2026-10-21
Q2 2026 Reduced 7,606 -49 (-0.6%) 0.67% $1,446,585 2026-07-29
Q1 2026 Added 7,655 +135 (1.8%) 0.65% $1,292,547 2026-04-21
Q4 2025 Unchanged 7,520 0 (0.0%) 0.63% $1,269,150 2026-02-02
Q3 2025 Reduced 7,520 -150 (-2.0%) 0.57% $1,085,662 2025-10-23
Q2 2025 Reduced 7,670 -277 (-3.5%) 0.55% $970,332 2025-07-22
Q1 2025 Unchanged 7,947 0 (0.0%) 0.67% $1,016,421 2025-05-08
Q4 2024 Reduced 7,947 -75 (-0.9%) 0.72% $1,050,673 2025-01-23
Q3 2024 Reduced 8,022 -3,024 (-27.4%) 0.85% $1,168,003 2024-10-25
Q2 2024 Reduced 11,046 -732 (-6.2%) 1.15% $1,516,174 2024-07-15
Q1 2024 Reduced 11,778 -213 (-1.8%) 1.32% $1,616,177 2024-04-26
Q4 2023 Reduced 11,991 -101 (-0.8%) 1.43% $1,628,977 2024-01-19
Q3 2023 Reduced 12,092 -95 (-0.8%) 1.45% $1,478,731 2023-10-24
Q2 2023 Reduced 12,187 -186 (-1.5%) 1.43% $1,547,262 2023-07-24
Q1 2023 Added 12,373 +78 (0.6%) 1.48% $1,598,097 2023-05-03
Q4 2022 Reduced 12,295 -289 (-2.3%) 1.59% $1,614,211 2023-02-06
Q3 2022 Unchanged 12,584 0 (0.0%) 1.62% $1,472,000 2022-11-01
Q2 2022 Unchanged 12,584 0 (0.0%) 1.52% $1,480,000 2022-07-22
Q1 2022 Reduced 12,584 -199 (-1.6%) 1.4% $1,640,000 2022-05-10
Q4 2021 Unchanged 12,783 0 (0.0%) 1.65% $1,951,000 2022-01-19
Five years are shown. A free account unlocks the complete reported history. Unlock full history
Institutional context

Who else reported the position

966 managers reported ISHARES BIOTECHNOLOGY ETF for Q2 2024.

Manager Activity Shares Change % of reported 13F Reported value Tenure
Bank of America Corporation Reduced 7,520,117 -114,023 0.09% $1,032,211,229 45 qtrs
The Goldman Sachs Group Inc Reduced 3,153,868 -58,897 0.07% $432,899,931 45 qtrs
Citigroup Inc Added 3,088,621 +502,072 0.27% $423,944,130 45 qtrs
MORGAN STANLEY Added 2,722,597 +18,043 0.03% $373,703,918 45 qtrs
JPMorgan Chase & Co Added 2,007,632 +398,907 0.02% $275,567,512 45 qtrs
BNP PARIBAS FINANCIAL MARKETS Reduced 1,841,330 -214,043 0.21% $252,740,956 42 qtrs
ROYAL BANK OF CANADA Reduced 1,277,536 -39,540 0.04% $175,354,000 45 qtrs
JANE STREET GROUP LLC Added 984,228 +879,388 0.03% $135,095,135 42 qtrs
UBS Group AG Reduced 905,610 -530,425 0.03% $124,304,029 39 qtrs
COMMERCE BANK Added 730,445 +8,419 0.65% $100,260,879 45 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
July 15, 2024
Filing type
13F-HR
Position type
ISHARES BIOTECH

Voting authority reported

Sole
11,046
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.